

RESEARCH

Open Access



Focal dose escalation for prostate cancer using ^{68}Ga -HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference

Constantinos Zamboglou^{1,8,9*} , Benedikt Thomann^{2,8}, Khodor Koubar^{2,8}, Peter Bronsert^{3,8}, Tobias Krauss^{5,8}, Hans C. Rischke^{1,8}, Ilias Sachpazidis^{2,8}, Vanessa Drendel^{3,8}, Nasr Salman^{1,8}, Kathrin Reichel^{6,8}, Cordula A. Jilg^{6,8}, Martin Werner^{3,8}, Philipp T. Meyer^{4,8}, Michael Bock^{7,8}, Dimos Baltas^{2,8} and Anca L. Grosu^{1,8}

Abstract

Background: Focal radiation therapy has gained of interest in treatment of patients with primary prostate cancer (PCa). The question of how to define the intraprostatic boost volume is still open. Previous studies showed that multiparametric MRI (mpMRI) or PSMA PET alone could be used for boost volume definition. However, other studies proposed that the combined usage of both has the highest sensitivity in detection of intraprostatic lesions. The aim of this study was to demonstrate the feasibility and to evaluate the tumour control probability (TCP) and normal tissue complication probability (NTCP) of radiation therapy dose painting using ^{68}Ga -HBED-CC PSMA PET/CT, mpMRI or the combination of both in primary PCa.

Methods: Ten patients underwent PSMA PET/CT and mpMRI followed by prostatectomy. Three gross tumour volumes (GTVs) were created based on PET (GTV-PET), mpMRI (GTV-MRI) and the union of both (GTV-union). Two plans were generated for each GTV. Plan95 consisted of whole-prostate IMRT to 77 Gy in 35 fractions and a simultaneous boost to 95 Gy (Plan95^{PET}/Plan95^{MRI}/Plan95^{union}). Plan80 consisted of whole-prostate IMRT to 76 Gy in 38 fractions and a simultaneous boost to 80 Gy (Plan80^{PET}/Plan80^{MRI}/Plan80^{union}). TCPs were calculated for GTV-histo (TCP-histo), which was delineated based on PCa distribution in co-registered histology slices. NTCPs were assessed for bladder and rectum.

Results: Dose constraints of published protocols were reached in every treatment plan. Mean TCP-histo were 99.7% (range: 97%–100%) and 75.5% (range: 33%–95%) for Plan95^{union} and Plan80^{union}, respectively. Plan95^{union} had significantly higher TCP-histo values than Plan95^{MRI} ($p = 0.008$) and Plan95^{PET} ($p = 0.008$). Plan80^{union} had significantly higher TCP-histo values than Plan80^{MRI} ($p = 0.012$), but not than Plan80^{PET} ($p = 0.472$). Plan95^{MRI} had significantly lower NTCP-rectum than Plan95^{union} ($p = 0.012$). No significant differences in NTCP-rectum and NTCP-bladder were observed for all other plans ($p > 0.05$).

Conclusions: IMRT dose escalation on GTVs based on mpMRI, PSMA PET/CT and the combination of both was feasible. Boosting GTV-union resulted in significantly higher TCP-histo with no or minimal increase of NTCPs compared to the other plans.

Keywords: Prostate cancer, Focal therapy, MRI, PSMA PET/CT

* Correspondence: constantinos.zamboglou@uniklinik-freiburg.de

¹Department of Radiation Oncology, Medical Center – University of Freiburg, Faculty of Medicine, Robert-Koch Straße 3, 79106 Freiburg, Germany

⁸German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany

Full list of author information is available at the end of the article



Background

Radiation therapy dose escalation for primary prostate cancer (PCa) can lower the risk of biochemical relapse [1]. Although toxicity from intensity modulated radiation therapy (IMRT) is manageable even at whole-prostate doses up to 86 Gy [2], recurrent PCa at the original tumour volume was still reported at this dose magnitude [3]. Therefore, further increase in dose escalation may be necessary to improve local tumour control [4]. In the last years, focal radiation therapy strategies evolved which limit normal tissue toxicity while enabling a further dose escalation to the tumour [5].

The exact delineation of the intraprostatic tumour mass is crucial for focal therapy strategies since the PCa volume should be covered by the imaging defined target region. Recently, two phase III trials (FLAME trial and HEIGHT trial) defined the intraprostatic boost volume by multiparametric MRI (mpMRI) [6]. However, first studies showed that PSMA PET/CT has a potential both in primary PCa detection and delineation [7, 8]. We examined the value of IMRT dose escalation on PSMA PET/CT-defined gross tumour volumes (GTVs) in a planning study. A boost of up to 95 Gy in 35 fractions resulted in significantly higher tumour control probability (TCP) values than a standard fractionation to the whole prostatic gland with 77 Gy in 35 fractions (96% vs. 70%). However, in 20% of the patients the dose escalation plans reached TCP values of around 80% [9].

In a comparison of PSMA PET and mpMRI for PCa detection, Eiber et al. [10] reported better area under the curve (AUC) values when PSMA PET and MRI information were combined, which we could confirm by performing a slice-by-slice comparison between mpMRI, PSMA PET/CT and histopathology after prostatectomy [11]. Sensitivities of 75%, 70% and 82% for PSMA PET, mpMRI and combined information were reported.

Furthermore, both studies pointed out that mpMRI and PSMA PET offer complementary information. However, there was a specificity of 67% for combined PSMA PET and mpMRI information [11], indicating that the combination may overestimate the true PCa amount within the prostate. Whether the increase in sensitivity and the decrease in specificity could be transferred to increased tumour control and normal tissue toxicity could not yet be answered.

The aim of this radiation therapy planning study was to demonstrate the technical feasibility of IMRT boosting based on GTVs derived from PSMA PET/CT, mpMRI or combined (PSMA PET and mpMRI) information in patients with primary PCa. Additionally, we compared the value of mpMRI, PSMA PET/CT and their combination for IMRT dose escalation guidance by calculating the TCPs based on the dose distribution in PCa within co-registered histology. The strength of this planning study is

that the TCP calculation is based on the histological data, while the radiation treatment planning is done based on multimodal imaging derived GTVs. The normal tissue complication probabilities (NTCPs) for bladder and rectum were calculated.

Methods

Patients

The study cohort consisted of 10 patients with primary PCa (intermediate and high risk according to NCCN-guidelines) who had PSMA PET/CT and mpMRI scans prior to radical prostatectomy. Their characteristics are described in Additional file 1: Table S1. Written informed consent was obtained from each patient, and the institutional review board approved this study.

PET/CT imaging


PET/CT scans using the ligand ^{68}Ga -HBED-CC-PSMA [12] were either performed with a 64-slice GEMINI TF PET/CT or a 16-slice GEMINI TF BIG BORE PET/CT (both Philips Healthcare, USA). A detailed description of our ^{68}Ga -HBED-CC-PSMA PET/CT imaging protocol is given in our previous publication [13]. To ensure the comparability of the quantitative measurements, both imaging systems were cross-calibrated. Patients underwent the whole-body PET scan starting 1 h after injection. The uptake of ^{68}Ga -PSMA-HBED-CC was quantified by standardized uptake values (SUV).

MR imaging

MR images were acquired either on a 3 Tesla system (Trio Tim, Siemens, Germany / 7 patients) or on a 1.5 Tesla system (Aera and Avanto, Siemens, Germany / 3 patients). All systems were equipped with a surface phased array (Body Matrix) in combination with an integrated spine array coil. No endo-rectal coil was used. Essentially, T2-weighted fast spin echo (T2W-TSE) images, diffusion weighted images (DWI) and dynamic contrast-enhanced (DCE) perfusion images were acquired. A detailed description of the MR imaging protocol is given in [13].

Image co-registration

After formalin-fixation, the resected prostate was placed in a special holder and a CT scan was performed. Subsequently, whole-mount step sections were cut using an in-house cutting device and processed by a board-certified pathologist. According to our previous study [11], histopathological information was digitalized to create GTV-histo and registered on in-vivo CT (PSMA PET/CT scans), taking into account the non-linear shrinkage and distortion of the resected prostate tissue (Fig. 1). Subsequently, in-vivo PET/CT datasets (including GTV-histo) were imported into iPlan (iPLAN RT image 4.1, BrainLAB, Germany). Axial TSE-, DWI- ADC maps and DCE-MRI images were



matched with in-vivo CT images using mutual information registration. If visual assessment showed an anatomical mismatch, a manual adjustment was performed based on anatomical markers. For alignment between PET and CT images the pre-set registration was used. Thus, CT/PET/MRI and histopathology data were registered in the same reference frame.

Generation of contours

Contours of the GTVs were generated in iPLAN. Based on our recent results, GTV-PET was created semi-automatically using a threshold of 30% of SUVmax within the prostate [7]. Two board-certified radiologists delineated GTV-MRI in consensus using T2W, DWI and DCE-sequences to characterize each lesion. Lesions with visually determined PI-RADs v2 [14] score 4 or higher were included in the analysis. With respect to PI-RADs v2 criteria, T2W-TSE and DWI images were primarily used for delineation of transition zone and peripheral zone lesions, respectively. The addition of GTV-PET and GTV-MRI was classified as GTV-union. Subsequently, the in-vivo CT including all above described GTVs was transferred to the RT planning system Eclipse v13.5 (Varian, USA) and contours for the prostate, seminal vesicles, and surrounding Organs at risk were generated. Clinical target volume 1 (CTV1) was defined as the prostate and the seminal vesicles. CTV2 was defined as the prostate and half of the seminal vesicles (high risk patients) or the basis of the seminal vesicles (intermediate risk patients). CTV1, CTV2, GTV-MRI, GTV-PET and GTV-union were enlarged by an isotropic margin of 4 mm to create the respective PTVs.

IMRT planning

Rapid Arc IMRT treatment plans were created in Eclipse v13.5 (Varian, USA). For each patient two different focal radiation therapy regimens were simulated. A moderate dose escalation was planned according to Pinkawa et al. [15] and a more intense dose escalation was planned in analogy to the experimental arm of the FLAME trial [6]. The simultaneous integrated boost was delivered based on PET (PTV-PET), MRI (PTV-MRI) or combined PSMA PET and mpMRI information (PTV-union).

1.) FLAME trial protocol

To simulate the experimental arm of the FLAME trial we planned 52.8 Gy in 24 fractions on PTV1 and 24.2 Gy in 11 fractions on PTV2 ($\text{EQD2}_{\alpha/\beta=3\text{Gy}} = 80$ Gy) with a concomitant boost to PTV-MRI (Plan95^{MRI}), PTV-PET (Plan95^{PET}), PTV-union (Plan95^{union}) with a dose of 95 Gy in 35 fractions ($\text{EQD2}_{\alpha/\beta=3\text{Gy}} = 109$ Gy). Dose constraints for bladder and rectum were taken from the FLAME protocol [6].

2.) Pinkawa et al. protocol

Treatment planning was performed according to [15]. We planned 54 Gy in 27 fractions on PTV1 and 22 Gy in 11 fractions on PTV2 ($\text{EQD2}_{\alpha/\beta=3\text{Gy}} = 76$ Gy) with a simultaneous dose escalation to PTV-MRI (Plan80^{MRI}), PTV-PET (Plan80^{PET}), PTV-union (Plan80^{union}) with a dose of 80 Gy in 38 fractions ($\text{EQD2}_{\alpha/\beta=3\text{Gy}} = 80$ Gy). Dose constraints for bladder and rectum were taken from the study protocol [15]. In case of an overlap between the boost volumes and the rectal wall a maximum dose to the rectum of up to 80 Gy was defined as a minor deviation.

During planning, dose constraints for the organs at risk had the highest priority. In order to achieve comparable plans for the different boost volumes the dose distribution within the corresponding PTVs was optimized to be as homogeneous as possible (see Additional file 2: Table S2a and 2b).

Radiobiological treatment plan evaluation

The TCP and NTCP calculations were performed using the research version of BIOTOP/BIOSPOT (Pi-medical, Greece) and MATLAB R2017a (The MathWorks, USA). The summation of 3D dose distributions, EQD2 as well as TCP and NTCP calculations were performed at voxel level. For TCP calculations, a radiobiological model based on the linear quadratic (LQ) Poisson model [16–20] was used. TCP calculations were performed based on GTV-histo (TCP-histo), assuming it to represent the true clinical response.

For the TCP calculations, we used the parameter $\alpha/\beta = 1.93$ [21] and the tumor cell density $\rho = 2.8 \times 10^8$ cells/cm³ for intermediate and high-risk patients [22–24]. The value for α ($\alpha = 0.1335 \text{ Gy}^{-1}$) was chosen in order to achieve an average TCP-histo value of 70% over all patients for the standard arm fractionation of the FLAME trial (77 Gy in 35 fractions) [6]. For a detailed description of the TCP calculation methodology performed in this study, please see Additional file 3 and our previous publication [9].

To calculate NTCPs of non-uniform dose distributions the relative seriality model was used [18, 25–27]. The following parameters were selected for bladder and rectum according to [28]. For bladder D50 = 80 Gy (symptomatic contracture and volume loss. EQD2), $s = 1.3$ and $\gamma = 2.59$ and for rectum D50 = 80 Gy (severe proctitis/necrosis/

stenosis/fistula. EQD2), $s = 0.75$ and $\gamma = 1.79$ were chosen. The γ -values were calculated based on the listed k -values [9]. For both organs, an α/β ratio of 3 Gy was assumed according to a recent study [29].

Statistical analysis

Statistical analyses were performed with Prism 7 (Graph-Pad, USA) and Microsoft Excel 2010 (Microsoft, USA). The Wilcoxon matched pairs signed-rank test was used with a threshold for statistical significance of < 0.05 .

Results

GTV-histo, GTV-PET, GTV-MRI and GTV-union in average amounted to $15 \pm 12\%$, $17 \pm 13\%$, $10 \pm 9\%$ and $20 \pm 14\%$ of the total intraprostatic volume (mean 54.17 ± 24.35 ml), respectively (Table 1).

In average, $86 \pm 10\%$, $74 \pm 17\%$ and $93 \pm 5\%$ of GTV-histo overlapped with PTV-PET, PTV-MRI and PTV-union, respectively (Fig. 2).

For all patients the target volume objectives as well as the OAR dose constraints were met. For Plan95^{PET}, Plan95^{MRI} and Plan95^{union} the mean doses for GTV-histo were 95.3 ± 2.6 Gy, 93.3 ± 2.6 Gy and 96.3 ± 1.5 Gy, respectively. For Plan80^{PET}, Plan80^{MRI} and Plan80^{union} the mean doses for GTV-histo were 80.7 ± 0.4 Gy, 79.9 ± 0.8 Gy and 80.8 ± 0.5 Gy, respectively. Additional file 4: Figure S1 shows dose volume histograms (DVHs) for GTV-histo, averaged for all plans and all patients.


TCP-histo values are listed in Table 2.

Plan95^{union} had significantly higher TCP-histo values than Plan95^{MRI} ($p = 0.008$) and Plan95^{PET} ($p = 0.008$). Plan80^{union} had significantly higher TCP-histo values than Plan80^{MRI} ($p = 0.012$). There were no significant differences in TCP-histo values between Plan80^{PET} and

Table 1 GTV volumes for each patient

Patient	% of prostatic volume				Volume prostate (ml)
	GTV-Histo	GTV-PET	GTV-MRI	GTV-union	
1	17%	39%	8%	41%	31.9
2	10%	23%	8%	24%	31.4
3	32%	25%	25%	36%	61.8
4	25%	9%	19%	22%	53.6
5	2%	2%	1%	2%	110.2
6	3%	4%	3%	5%	48.7
7	2%	3%	1%	4%	70
8	4%	10%	4%	11%	60
9	19%	24%	22%	33%	26.5
10	33%	26%	10%	26%	47.6
Mean	15%	17%	10%	20%	54.2
SD \pm	12%	13%	9%	14%	24.4

GTV-histo was not significantly smaller than GTV-union ($p = 0.1$) and GTV-PET ($p = 0.715$) but significant larger than GTV-MRI ($p = 0.047$) in Wilcoxon matched pairs signed-rank test. Mean prostatic volume (delineated in CT) was 54.2 ± 24.4 ml



Plan80^{union} ($p = 0.472$). Whether the dose escalation was delivered based on PET or mpMRI information had no impact on TCP-histo values for both protocols ($p > 0.05$, Fig. 3).

NTCP calculations for bladder and rectum revealed no significant differences for all plans ($p > 0.05$, Fig. 4), with the exception that Plan95^{MRI} had significantly lower NTCP-rectum values than Plan95^{union} ($p = 0.012$) and Plan95^{PET} ($p = 0.047$), respectively.

Discussion

A reliable delineation of the intraprostatic tumor burden is a prerequisite for implementation of focal therapy approaches in treatment of primary PCa. Most of the published studies used mpMRI to define the target for focal therapy guidance [5]. Our group [7] and others [8, 30] illustrated a great potential for PSMA PET/CT based delineation of primary PCa. However, two recent studies examined the role of combined PSMA PET and mpMRI information for primary PCa localization based on histology reference. Both reported higher sensitivities when the combined information was used compared to PSMA PET or mpMRI alone [10, 11]. Accordingly, we could show in this study that GTV-histo overlapped significantly higher with PTV-union, which was generated based on

combined mpMRI and PSMA PET information, than with PTV-PET or PTV-MRI alone. Furthermore, mean GTV-union was slightly larger than mean GTV-PET ($p > 0.05$) and mean GTV-histo ($p > 0.05$) and it was significantly larger than GTV-MRI ($p < 0.05$). The main questions for this study were whether a focal dose escalation, which is guided by combined PSMA PET and mpMRI information, is technically feasible and if an increase in TCP values is achieved compared to boosting GTVs based on PSMA PET or mpMRI alone. We performed TCP-histo calculations based on registered histological information after prostatectomy, which should correlate with the real PCa distribution and should also predict the true clinical outcome.

This study confirmed the technical feasibility for prescription doses and dose constraints of the FLAME trial [6] and Pinkawa et al. [15]. These two clinical protocols were chosen since they applied different prescription doses for the prostate (EQD2 _{$\alpha/\beta=3\text{Gy}$} = 76 Gy [15] and 80 Gy [6]) and the boost volume (EQD2 _{$\alpha/\beta=3\text{Gy}$} = 80 Gy [15] and 109 Gy [6]) using similar fractions. NTCP values for rectum and bladder were identical for all plans, except of a slight decrease in NTCP-rectum values for Plan95^{MRI} (mean NTCP-rectum was 1.09 for Plan95^{MRI}, 1.41 for Plan95^{PET} and 1.42 for Plan95^{union}).

TCP-histo values were significantly higher for Plan95^{union} and Plan80^{union} compared to the plans in which the boost volume was derived from mpMRI or PSMA PET/CT alone. This observation can most likely be ascribed to the high overlap between PTV-union and GTV-histo. In average 86%, 74% and 93% of GTV-histo overlapped with PTV-MRI, PTV-PET and PTV-union, respectively. For Plan80, the assumed correlation between GTV-histo coverage and resulting TCP-histo was confirmed as the mean TCP-histo was indeed higher for Plan80^{PET} than it was for Plan80^{MRI}. Interestingly though, for Plan95^{MRI} the mean TCP-histo was higher than for Plan95^{PET}. A good coverage of the main PCa mass by PTV-MRI serves as an explanation for this observation. Since the FLAME protocol delivers a higher dose to the entire prostate than the Pinkawa protocol (difference of EQD2 _{$\alpha/\beta=3\text{Gy}$} = 4 Gy), missing small PCa lesions with the boost volume has a lower impact on the TCP for the FLAME protocol than it has for the Pinkawa protocol. For ultra-focal therapy approaches like high intensity focused ultrasound (HIFU) [31], or focal low-/high-dose rate brachytherapy [32, 33] the treatment is focused

Table 2 TCP-histo values

	Plan95 ^{PET}	Plan95 ^{MRI}	Plan95 ^{union}	Plan80 ^{PET}	Plan80 ^{MRI}	Plan80 ^{union}
Mean (%)	94.7	96.9	99.7	73.0	70.8	75.5
Maximum (%)	100.0	100.0	100.0	94.0	94.0	95.2
Minimum (%)	69.6	86.4	97.4	25.1	30.2	33.0

Mean, maximum and minimum TCP-histo values over all patients for all plans are listed




Fig. 3 The middle horizontal bars represent the mean values and the upper and lower bars the respective maximum and minimum values. Wilcoxon matched pairs signed-rank test showed that Plan95^{Union} had significantly higher TCP values than both Plan95^{MRI} and Plan95^{PET}, respectively ($p < 0.05$). Plan80^{Union} only had significantly higher TCP values than Plan80^{MRI} ($p < 0.05$) but not than Plan80^{PET} ($p = 0.5$). There were no significant differences in TCP-histo values between Plan80/95^{MRI} and Plan80/95^{PET} ($p = 0.371$ for Plan80 and $p = 0.844$ for Plan95)

solely within the imaging defined target or region. Thus, a high coverage of the PCa mass may be even more crucial than for the two IMRT protocols which were used in this study.

As expected, TCP-histo values for Plan95 had a much lower range than TCP-histo values for Plan80^{Union} (Fig. 3 and Table 2), indicating that the intensity of dose escalation has a higher impact than the modality which was chosen for boost-volume delineation. Dose escalation up to 95 Gy on PTV-PET and PTV-MRI alone reached excellent results (TCP-histo $> 95\%$) in 8 of 10 patients. Furthermore, only a small difference in mean TCP-histo values between Plan80^{PET} and Plan80^{Union} was measured (73% vs. 76). This might be seen as an indicator that a single imaging modality (PSMA PET or mpMRI) is sufficient for GTV-delineation, particularly when considering the overutilization of diagnostic imaging in current health systems [34]. However, several studies showed that PSMA PET and mpMRI offer complementary information

in detection of primary PCa [10, 11, 13]. 22% [11] to 32% [10] of prostatic areas were classified as positive by one modality and negative by the other. Furthermore, we found very little to no differences in NTCP values for bladder and rectum between the plans. Future studies are needed to characterize those patient populations (e.g. by Gleason score or PSA serum levels) in which a combined usage of PSMA PET and mpMRI is necessary and to differentiate them from the remaining majority of cases where only a single imaging modality is sufficient. Until this question is finally answered, the combined usage of PET and mpMRI for GTV-delineation ensures the best therapeutic ratio.

Beyond GTV-delineation for dose escalation guidance, the combined usage of mpMRI and PSMA PET/CT offers further advantages in the clinical workflow of patients with primary PCa. MRI provides a better soft tissue contrast than CT images and is likewise superior for prostatic gland delineation [35]. On the other hand,




Fig. 4 For all patients NTCP values for bladder and rectum were presented for all plans. The middle bars represent the mean values and the upper and lower bars the standard deviations. Wilcoxon matched pairs signed-rank test showed that no significant differences in NTCP values for the different Plans when dose was delivered in analogy to the Pinkawa protocol ($p > 0.05$). When dose was delivered in analogy to the Flame trial a significant reduction in NTCP-rectum values was observed for Plan95^{MRI} compared to Plan95^{Union} ($p = 0.012$) and Plan95^{PET} ($p = 0.047$). There were no significant differences in NTCP-bladder values for Plan95 ($p > 0.05$)

PSMA PET/CT is superior in lymph node [36] and skeletal [37] staging compared to conventional imaging, indicating that PSMA PET/CT may also be used as a “one-stop shop staging” modality for patients with intermediate and high-risk PCa.

An important issue of this study is the uncertainty in registration of PET/CT, mpMRI and histopathology (e.g. non-linear shrinkage of the prostate after prostatectomy or different rectum and bladder fillings during imaging) [38]. The usage of hybrid PET/MRI systems [10] might account for the registration uncertainties between the PET and mpMRI, but these systems are currently not widely available. A second issue of this study is the margin used for PTV generation since the PTV affects the NTCP (dose to rectum and bladder) as well as the TCP (potential shifts of GTV-histo out of the dose escalation area). The FLAME trial (5–8 mm) [39] and the Pinkawa protocol (3–8 mm) [15] used larger PTV margins around the prostate than our study. On the other hand, the Pinkawa protocol [15] applied a margin of 3–4 mm to create the intraprostatic dose escalation volume and the FLAME trial [39] used no margin for this at all. In the current study we expanded both the prostate and the intraprostatic GTVs with an isotropic margin of 4 mm to create the respective PTVs. At our department the patients with primary PCa receive daily fiducial marker-based position verification to account for inter-fractional movements. Additionally, an adaptive radiotherapy [40] protocol based on repeated cone-beam CT scans was established in order to calculate the average position of the targets and the organs at risk. Therefore, at our department the PTV mainly accounts for the intrafractional movement during IMRT (maximum movement of 2 mm in > 85% of datasets after 6 min of RT [41]) and possible registration errors between CT and MRI information (approx. 2 mm [42]). The usage of 4 mm margins around the prostate in our study could be considered as a possible reason for keeping the dose constraints for rectum and bladder. However, a planning study by Lips et al. [43] simulated an intraprostatic dose escalation and analyzed the effect of different margins (2–8 mm) around the prostate on the dose distributions for bladder and rectum. The authors observed that the dose constraints for both organs were met for all margins. Our group simulated intrafractional movement during PSMA PET guided simultaneous integrated boost IMRT for patients with primary PCa [44]. By using the same PTV margins as the current study we showed that intrafractional movement in average does not have any significant effect on the TCP and can even increase the TCP if the boost volume is surrounded by a sufficiently high dose plateau.

Another potential limitation of this study is that the clinically derived parameters of the biological model used

in this study have not been validated through prospective clinical trials. To account for this issue a previous planning study used 15 different parameter value combinations for TCP calculations. The observed variance between the TCP-histo values for the different parameter value sets was low [9], which justifies the approach in this study.

In summary, we could show in 10 patients that the concept of a focal dose escalation is feasible on GTVs delineated by combined PSMA PET and mpMRI information. High TCPs were achieved with acceptable NTCPs. These findings need to be further validated in a prospective dose escalation trial for patients with primary PCa.

Conclusion

In patients with primary PCa IMRT dose escalation is feasible using GTVs defined on multimodal image data (mpMRI and PSMA PET/CT). It achieves significantly higher TCP-histo values with minimal to no increase of NTCP values compared to IMRT dose escalation on GTVs derived solely based on one imaging modality.

Additional files

Additional file 1: Table S1. Patient characteristics. (PDF 106 kb)

Additional file 2: Tables S2a + b. 1. FLAME protocol / 2. Pinkawa protocol. Dose characteristics after IMRT planning based on different protocols (PDF 82 kb)

Additional file 3: A. Additional information on TCP calculation / B. Additional information on NTCP calculation. (PDF 278 kb)

Additional file 4: Figure S1. Dose volume histograms (DVHs) for GTV-histo, averaged for all plans and all patients. (PDF 169 kb)

Abbreviations

approx: Approximately; AUC: Area under the curve; CT: Computer tomography; CTV1: Clinical target volume; DCE: Dynamic contrast-enhanced images; DWI: Diffusion weighted images; EQD2: Equivalent dose in 2 Gy per fraction; GTV: Gross tumour volume; Gy: Gray; IMRT: Intensity modulated radiation therapy; MRI: Magnetic resonance imaging; NTCP: Normal tissue complication probability; PCa: Prostate cancer; PET: Positron emission tomography; PTV: Planning target volume; SUV: Standardized uptake value; T2W-TSE: T2-weighted fast spin echo images; TCP: Tumour control probability

Funding

The study was funded from house internal budget.

Availability of data and materials

The datasets used and/or analyses during the current study are available from the corresponding author on reasonable request.

Authors' contributions

CZ and BT analysed and CZ, BT and ALG interpreted the data. CZ, ALG and BT performed the statistical analysis and were contributors in writing the manuscript. HCR, PTM and TK helped generating the GTVs (data acquisition). MB was concerned with the MRI sequences. KR and CAJ performed the prostatectomies. PB, VD and MW performed the histopathological preparation of the data. KK and BT did the IMRT planning. IS and DB were responsible for biological modelling. ALG supervised the whole project. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The University of Freiburg ethics committee approved the study and written informed consent was obtained from all participants.

Consent for publication

Written informed consent for publication was obtained from all participants.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Radiation Oncology, Medical Center – University of Freiburg, Faculty of Medicine, Robert-Koch Straße 3, 79106 Freiburg, Germany.

²Division of Medical Physics, Department of Radiation Oncology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany.

³Department of Pathology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. ⁴Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany.

⁵Department of Radiology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. ⁶Department of Urology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. ⁷Division of Medical Physics, Department of Radiology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany. ⁸German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.

⁹Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Received: 7 March 2018 Accepted: 26 April 2018

Published online: 02 May 2018

References

- Kupelian PA, Ciezki J, Reddy CA, Klein EA, Mahadevan A. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2008;71(1):16–22.
- Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2013;85(3):686–92.
- Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. *Int J Radiat Oncol Biol Phys*. 2002;53(3):595–9.
- Martinez AA, Gonzalez J, Ye H, Ghilezan M, Shetty S, Kernen K, et al. Dose escalation improves Cancer-related events at 10 years for intermediate- and high-risk prostate Cancer patients treated with Hypofractionated high-dose-rate boost and external beam radiotherapy. *Int J Radiat Oncol*. 2011;79(2):363–70.
- Bauman G, Haider M, Van der Heide UA, Menard C. Boosting imaging defined dominant prostatic tumors: a systematic review. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2013;107(3):274–81.
- Lips IM, van der Heide UA, Haustermans K, van Lin EN, Pos F, Franken SP, et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. *Trials*. 2011;12:255.
- Zamboglou C, Schiller F, Fechter T, Wieser G, Jilg CA, Chirindel A, et al. (68)Ga-HBED-CC-PSMA PET/CT versus histopathology in primary localized prostate Cancer: a voxel-wise comparison. *Theranostics*. 2016;6(10):1619–28.
- Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, et al. Correlation of Intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate Cancer. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2016;57(4):563–7.
- Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S, et al. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: a planning study based on histopathology reference. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2017;123(3):472–7.
- Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate Cancer. *Eur Urol*. 2016;70:829–36.
- Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, et al. Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. *Theranostics*. 2017;7(1):228–37.
- Eder M, Neels O, Muller M, Bauder-Wust U, Remde Y, Schafer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate Cancer. *Pharmaceuticals*. 2014;7(7):779–96.
- Zamboglou C, Wieser G, Hennies S, Rempel I, Kirste S, Soschynski M, et al. MRI versus (68)Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. *Eur J Nucl Med Mol Imaging*. 2016;43(5):889–97.
- Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2. *Eur Urol*. 2016;69(1):16–40.
- Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. *Radiat Oncol*. 2012;7:14.
- Munro TR, Gilbert CW. The relation between tumour lethal doses and the radiosensitivity of tumour cells. *Br J Radiol*. 1961;34:246–51.
- Brahme A, Agren AK. Optimal dose distribution for eradication of heterogeneous tumours. *Acta Oncol*. 1987;26(5):377–85.
- Lind BK, Mavroidis P, Hyodynmaa S, Kappas C. Optimization of the dose level for a given treatment plan to maximize the complication-free tumor cure. *Acta Oncol*. 1999;38(6):787–98.
- Wheldon TE, Deehan C, Wheldon EG, Barrett A. The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 1998;46(3):285–95.
- Yorke ED. Modeling the effects of inhomogeneous dose distributions in normal tissues. *Seminars In Radiation Oncology*. 2001;11(3):197–209.
- Vogelius IR, Bentzen SM. Meta-analysis of the alpha/Beta ratio for prostate Cancer in the presence of an overall time factor: bad news, good news, or no news? *Int J Radiat Oncol*. 2013;85(1):89–94.
- Casares-Magaz O, van der Heide UA, Rorvik J, Steenbergen P, Muren LP. A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps. *Radiother Oncol*. 2016;119(1):111–6.
- Chang JH, Joon DL, Lee ST, Gong SJ, Anderson NJ, Scott AM, et al. Intensity modulated radiation therapy dose painting for localized prostate Cancer using C-11-choline positron emission tomography scans. *Int J Radiat Oncol*. 2012;83(5):E691–E6.
- Ghobadi G, de Jong J, Hollmann BG, van Triest B, van der Poel HG, Vens C, et al. Histopathology-derived modeling of prostate cancer tumor control probability: implications for the dose to the tumor and the gland. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2016;119(1):97–103.
- Kallman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. *Int J Radiat Biol*. 1992;62(2):249–62.
- Lyman JT. Complication probability as assessed from dose-volume histograms. *Radiat Res Suppl*. 1985;8:S13–9.
- Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. *Int J Radiat Oncol Biol Phys*. 1989;16(6):1623–30.
- Takam R, Bezak E, Yeoh EE, Marcu L. Assessment of normal tissue complications following prostate cancer irradiation: comparison of radiation treatment modalities using NTCP models. *Med Phys*. 2010;37(9):5126–37.
- Kuang Y, Wu L, Hirata E, Miyazaki K, Sato M, Kwee SA. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT. *Int J Radiat Oncol Biol Phys*. 2015;91(5):1017–25.
- Rhee H, Thomas P, Shepherd B, Greenslade S, Vela I, Russell PJ, et al. Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance

- imaging in localized prostate Cancer as confirmed by whole mount histopathology. *J Urol*. 2016;196(4):1261–7.
31. Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. *Urology*. 2004;63(2):297–300.
 32. Zamboglou C, Rischke HC, Meyer PT, Knobe S, Volgeova-Neher N, Kollefrath M, et al. Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. *Journal of contemporary brachytherapy*. 2016;8(3):241–8.
 33. Langley S, Ahmed HU, Al-Qaisieh B, Bostwick D, Dickinson L, Veiga FG, et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. *BJU Int*. 2012;109(Suppl 1):7–16.
 34. Hendee WR, Becker GJ, Borgstede JP, Bosma J, Casarella WJ, Erickson BA, et al. Addressing overutilization in medical imaging. *Radiology*. 2010;257(1):240–5.
 35. Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque JV. Definition of the prostate in CT and MRI: a multi-observer study. *Int J Radiat Oncol*. 1999;43(1):57–66.
 36. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate Cancer. *J Urol*. 2016;195(5):1436–43.
 37. Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. *Eur J Nucl Med Mol Imaging*. 2016;43:2114–21.
 38. Schiller F, Fechter T, Zamboglou C, Chirindel A, Salman N, Jilg CA, et al. Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation. *EJNMMI physics*. 2017;4(1):21.
 39. Monnikhof EM, van Loon JW, van Vulpen M, Kerkmeijer LGW, Pos FJ, Haustermans K, et al. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial. *Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology*. 2018.
 40. Ghilezan M, Yan D, Martinez A. Adaptive radiation therapy for prostate cancer. *Semin Radiat Oncol*. 2010;20(2):130–7.
 41. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. *Int J Radiat Oncol Biol Phys*. 2008;72(1):236–46.
 42. Dean CJ, Sykes JR, Cooper RA, Hatfield P, Carey B, Swift S, et al. An evaluation of four CT-MRI co-registration techniques for radiotherapy treatment planning of prone rectal cancer patients. *Brit J Radiol*. 2012; 85(1009):61–8.
 43. Lips IM, van der Heide UA, Kotte AN, van Vulpen M, Bel A. Effect of translational and rotational errors on complex dose distributions with off-line and on-line position verification. *Int J Radiat Oncol Biol Phys*. 2009;74(5):1600–8.
 44. Thomann B, Sachpazidis I, Koubar K, Zamboglou C, Mavroidis P, Wiehle R, et al. Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer. *Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology*. 2018.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

